Pharmacokinetics and safety of CT-P17 (40 mg/0.4 ml) versus reference adalimumab: randomized study in healthy Japanese adults. Supplementary methods
收藏数据链接：
官方服务：
资源简介：
Pharmacokinetics & safety of CT-P17 (40 mg/0.4 mL) vs reference adalimumab: randomised study in healthy Japanese adults: supplementary methods
创建时间：
2023-02-07
